



U. S. Department of Justice

Drug Enforcement Administration
Office of Chief Counsel
Diversion/Regulatory Section

December 19, 1997

Simone Monasebian, Esq.
Law Offices of Michael Kennedy
425 Park Avenue, 26th Floor
New York, New York 10032

Re: Petition of Jon Gettman and Trans-High Corporation

Dear Ms. Monasebian:

Please be advised that the above-referenced petition, which requests initiation of proceedings for a repeal of the rules or regulations that place marijuana and THC in Schedule I and dronabinol product and nabilone in Schedule II of the Controlled Substances Act, has been forwarded to the Acting Assistant Secretary for Health of the Department of Health and Human Services (DHHS) for review pursuant to 21 U.S.C. § 811(b) and 21 C.F.R. § 1308.43(d). In accordance with these provisions, the Acting Assistant Secretary has been requested to provide a scientific and medical evaluation of the available data and to provide a scheduling recommendation for the substances at issue in the petition. Once the DEA receives the requested evaluation and recommendation from DHHS, and after consideration of that and all other relevant information, a decision will be made whether to initiate proceedings as requested by the petitioners. You will then be notified of such decision.

If you have any questions or comments, please do not hesitate to contact me at (202) 307-8010.

Very truly yours,

Mary Kate Whalen
Mary Kate Whalen, Esq.

CC: Frank Sapienza, Chief
Office of Drug Evaluation